NASDAQ:BDTX Black Diamond Therapeutics (BDTX) Stock Price, News & Analysis $6.20 -0.03 (-0.48%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$6.09▼$6.5050-Day Range$4.21▼$6.2452-Week Range$1.62▼$7.66Volume224,344 shsAverage Volume660,339 shsMarket Capitalization$348.75 millionP/E RatioN/ADividend YieldN/APrice Target$13.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Black Diamond Therapeutics alerts: Email Address Black Diamond Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside109.7% Upside$13.00 Price TargetShort InterestBearish8.41% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.45Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.47) to ($1.00) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.73 out of 5 starsMedical Sector692nd out of 936 stocksBiological Products, Except Diagnostic Industry114th out of 154 stocks 3.5 Analyst's Opinion Consensus RatingBlack Diamond Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBlack Diamond Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Black Diamond Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.41% of the outstanding shares of Black Diamond Therapeutics have been sold short.Short Interest Ratio / Days to CoverBlack Diamond Therapeutics has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in Black Diamond Therapeutics has recently increased by 47.35%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBlack Diamond Therapeutics does not currently pay a dividend.Dividend GrowthBlack Diamond Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BDTX. Previous Next 2.5 News and Social Media Coverage News SentimentBlack Diamond Therapeutics has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Black Diamond Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 4 people have searched for BDTX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows7 people have added Black Diamond Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Black Diamond Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.87% of the stock of Black Diamond Therapeutics is held by insiders.Percentage Held by Institutions95.47% of the stock of Black Diamond Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Black Diamond Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Black Diamond Therapeutics are expected to grow in the coming year, from ($1.47) to ($1.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Black Diamond Therapeutics is -3.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Black Diamond Therapeutics is -3.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBlack Diamond Therapeutics has a P/B Ratio of 2.74. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Black Diamond Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Find out details on these three critical Nvidia partners immediately. About Black Diamond Therapeutics Stock (NASDAQ:BDTX)Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Read More BDTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BDTX Stock News HeadlinesJuly 18, 2024 | americanbankingnews.comShort Interest in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Rises By 8.4%June 1, 2024 | globenewswire.comBlack Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual MeetingJuly 27, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.May 29, 2024 | globenewswire.comBlack Diamond Therapeutics to Participate in Jefferies Global Healthcare ConferenceMay 22, 2024 | finance.yahoo.comBlack Diamond Therapeutics, Inc. (NASDAQ:BDTX) is favoured by institutional owners who hold 60% of the companyMay 10, 2024 | msn.comShould You Buy Black Diamond Therapeutics (BDTX) Ahead of Earnings?May 9, 2024 | sfgate.comBlack Diamond: Q1 Earnings SnapshotMay 9, 2024 | globenewswire.comBlack Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateJuly 27, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.April 24, 2024 | globenewswire.comBlack Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingApril 11, 2024 | globenewswire.comBlack Diamond Therapeutics Announces Changes to Board of DirectorsApril 8, 2024 | finance.yahoo.comWall Street Analysts Predict a 129.25% Upside in Black Diamond (BDTX): Here's What You Should KnowApril 7, 2024 | globenewswire.comBlack Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual MeetingApril 3, 2024 | globenewswire.comBlack Diamond Therapeutics to Participate in Upcoming Investor ConferencesMarch 14, 2024 | finance.yahoo.comBlack Diamond Therapeutics Inc (BDTX) Reports Q4 and Full Year 2023 Financials, Advances ...March 12, 2024 | globenewswire.comBlack Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 5, 2024 | globenewswire.comBlack Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024February 29, 2024 | seekingalpha.comBDTX Black Diamond Therapeutics, Inc.See More Headlines Receive BDTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Black Diamond Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BDTX CUSIPN/A CIK1701541 WebN/A Phone617-252-0848FaxN/AEmployees90Year FoundedN/APrice Target and Rating Average Stock Price Target$13.00 High Stock Price Target$16.00 Low Stock Price Target$11.00 Potential Upside/Downside+111.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-82,440,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-72.94% Return on Assets-53.79% Debt Debt-to-Equity RatioN/A Current Ratio7.05 Quick Ratio7.05 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.26 per share Price / Book2.72Miscellaneous Outstanding Shares56,250,000Free Float51,263,000Market Cap$345.38 million OptionableOptionable Beta2.49 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Mark A. Velleca M.D. (Age 60)Ph.D., CEO, President & Chairman Comp: $795.98kDr. David M. Epstein Ph.D. (Age 65)Co-Founder & Director Comp: $969.69kDr. Fang Ni Pharm.D. (Age 37)CFO, Principal Financial Officer and Chief Business Officer Comp: $665.98kDr. Sergey Yurasov M.D. (Age 55)Ph.D., Chief Medical Officer Comp: $718.92kDr. Elizabeth Buck Ph.D. (Age 49)Co-Founder & Chief Scientific Officer Comp: $340.47kMr. Brent Hatzis-Schoch Esq. (Age 59)J.D., COO & General Counsel Comp: $683.29kMs. Elizabeth L. Montgomery (Age 52)Chief People Officer Ms. Melanie Morrison (Age 49)Chief Development Officer Ms. Erika Jones (Age 39)Senior VP of Finance & Corporate Controller More ExecutivesKey CompetitorsSpectrum PharmaceuticalsNASDAQ:SPPIInhibrxNASDAQ:INBXCompugenNASDAQ:CGENSana BiotechnologyNASDAQ:SANAVir BiotechnologyNASDAQ:VIRView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 108,959 shares on 7/26/2024Ownership: 0.194%SG Americas Securities LLCBought 23,146 shares on 7/12/2024Ownership: 0.041%Artal Group S.A.Sold 1,000,000 shares on 5/17/2024Ownership: 1.860%Kennedy Capital Management LLCSold 23,718 shares on 5/16/2024Ownership: 1.275%Bellevue Group AGSold 18,000 shares on 5/15/2024Ownership: 15.142%View All Insider TransactionsView All Institutional Transactions BDTX Stock Analysis - Frequently Asked Questions How have BDTX shares performed this year? Black Diamond Therapeutics' stock was trading at $2.81 at the beginning of 2024. Since then, BDTX shares have increased by 120.6% and is now trading at $6.20. View the best growth stocks for 2024 here. How were Black Diamond Therapeutics' earnings last quarter? Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) posted its quarterly earnings data on Thursday, May, 9th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.09. When did Black Diamond Therapeutics IPO? Black Diamond Therapeutics (BDTX) raised $151 million in an initial public offering on Thursday, January 30th 2020. The company issued 8,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies and Cowen acted as the underwriters for the IPO and Canaccord Genuity was co-manager. Who are Black Diamond Therapeutics' major shareholders? Black Diamond Therapeutics' top institutional shareholders include Bank of New York Mellon Corp (0.19%) and SG Americas Securities LLC (0.04%). Insiders that own company stock include Growth N V Biotech, Ali Behbahani, David M Epstein and Fang Ni. View institutional ownership trends. How do I buy shares of Black Diamond Therapeutics? Shares of BDTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Black Diamond Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Black Diamond Therapeutics investors own include Alector (ALEC), Alteryx (AYX), Editas Medicine (EDIT), Gossamer Bio (GOSS), Micron Technology (MU), NVIDIA (NVDA) and Homology Medicines (FIXX). This page (NASDAQ:BDTX) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Black Diamond Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Black Diamond Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BDTX Stock Alerts